Adamas Pharmaceuticals, Inc. (ADMS) PT Set at $45.00 by Cowen and Company

Cowen and Company set a $45.00 target price on Adamas Pharmaceuticals, Inc. (NASDAQ:ADMS) in a research note released on Wednesday, August 9th. The brokerage currently has a buy rating on the specialty pharmaceutical company’s stock.

Several other analysts have also commented on ADMS. Zacks Investment Research lowered Adamas Pharmaceuticals from a hold rating to a sell rating in a research note on Wednesday, May 3rd. Noble Financial reaffirmed a buy rating on shares of Adamas Pharmaceuticals in a research note on Friday, May 12th. Mizuho reaffirmed a buy rating and issued a $26.00 price target on shares of Adamas Pharmaceuticals in a research note on Tuesday, June 6th. Finally, BidaskClub lowered Adamas Pharmaceuticals from a hold rating to a sell rating in a research note on Wednesday, July 19th. Two equities research analysts have rated the stock with a sell rating and four have given a buy rating to the company’s stock. The company has an average rating of Hold and a consensus target price of $29.00.

Adamas Pharmaceuticals (NASDAQ:ADMS) traded up 1.93% during trading on Wednesday, hitting $14.29. 595,064 shares of the stock traded hands. The company’s 50 day moving average price is $16.83 and its 200-day moving average price is $16.80. The stock’s market cap is $321.73 million. Adamas Pharmaceuticals has a 52-week low of $12.10 and a 52-week high of $19.50.

Adamas Pharmaceuticals (NASDAQ:ADMS) last released its quarterly earnings data on Tuesday, August 8th. The specialty pharmaceutical company reported ($0.93) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.81) by $0.12. The firm had revenue of $0.02 million for the quarter, compared to the consensus estimate of $0.03 million. Adamas Pharmaceuticals had a negative net margin of 10,499.65% and a negative return on equity of 52.91%. The business’s revenue for the quarter was down 90.9% on a year-over-year basis. During the same quarter in the prior year, the firm posted ($0.78) earnings per share. Equities research analysts forecast that Adamas Pharmaceuticals will post ($3.80) earnings per share for the current fiscal year.

COPYRIGHT VIOLATION WARNING: This story was originally posted by [[site]] and is owned by of [[site]]. If you are accessing this story on another site, it was stolen and reposted in violation of international copyright & trademark legislation. The correct version of this story can be viewed at [[permalink]].

In other Adamas Pharmaceuticals news, major shareholder Great Point Partners Llc sold 350,000 shares of the business’s stock in a transaction on Monday, June 19th. The stock was sold at an average price of $17.05, for a total value of $5,967,500.00. The transaction was disclosed in a document filed with the SEC, which is available at this link. In the last three months, insiders sold 731,041 shares of company stock worth $12,476,149. Insiders own 29.00% of the company’s stock.

Institutional investors have recently bought and sold shares of the company. Vanguard Group Inc. raised its position in Adamas Pharmaceuticals by 4.0% in the second quarter. Vanguard Group Inc. now owns 745,237 shares of the specialty pharmaceutical company’s stock worth $13,034,000 after buying an additional 28,818 shares in the last quarter. Alliancebernstein L.P. raised its position in shares of Adamas Pharmaceuticals by 2.6% in the second quarter. Alliancebernstein L.P. now owns 717,617 shares of the specialty pharmaceutical company’s stock valued at $12,551,000 after buying an additional 17,972 shares during the period. Emerald Advisers Inc. PA raised its position in shares of Adamas Pharmaceuticals by 2.7% in the second quarter. Emerald Advisers Inc. PA now owns 532,727 shares of the specialty pharmaceutical company’s stock valued at $9,317,000 after buying an additional 14,042 shares during the period. State Street Corp raised its position in shares of Adamas Pharmaceuticals by 9.1% in the second quarter. State Street Corp now owns 285,359 shares of the specialty pharmaceutical company’s stock valued at $4,990,000 after buying an additional 23,708 shares during the period. Finally, Granite Point Capital Management L.P. raised its position in shares of Adamas Pharmaceuticals by 11.9% in the second quarter. Granite Point Capital Management L.P. now owns 263,515 shares of the specialty pharmaceutical company’s stock valued at $4,609,000 after buying an additional 28,000 shares during the period. 70.86% of the stock is currently owned by institutional investors.

Adamas Pharmaceuticals Company Profile

Adamas Pharmaceuticals, Inc is a pharmaceutical company. The Company is engaged in developing medicines to manage the daily lives of those affected by chronic neurologic disorders. It offers a platform based on an understanding of time dependent biologic effects of disease activity and drug response to achieve relief without tolerability issues.